SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending amidst heightened market uncertainty driven by recent geopolitical rhetoric from the US administration regarding tariffs and Greenland, alongside concerns about the stability of the Japanese bond market. The community is sharply divided, with many predicting significant short-term downside, while others expect a swift market recovery after initial drops.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is trending as discussions are dominated by escalating geopolitical tensions following former President Trump's threats of tariffs against European nations over Greenland. This news has triggered significant drops in futures, leading to polarized community sentiment: some foresee a 'bloody Tuesday,' while others confidently expect a quick 'V-shaped' recovery, anticipating aggressive 'buy the dip' action amid these trade concerns.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as its Anktiva therapy receives broad international approval for lung and other cancers, drawing immense community discussion around its potential to revolutionize oncology. Investors are actively debating a substantial short squeeze and a paradigm shift in cancer treatment, fueled by the company's innovative immunotherapy platform and recent commercial momentum. The conversation highlights the global impact of this therapeutic approach and calls for broader regulatory recognition.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is experiencing strong bullish momentum following its presentation of breakthrough pancreatic cancer trial data at the JPM Healthcare Conference, where its Alpha DaRT technology's unique immune-preserving properties garnered significant attention. The community is actively discussing the stock, fueled by widespread anticipation of imminent Japanese regulatory approval and whispers of institutional buying. This positions the innovative oncology treatment for a potential re-rating as awareness of its revolutionary potential grows.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is actively trending, fueled by its aggressive expansion in the artificial intelligence sector, notably a new data center lease deal with RIOT Platforms to support significant AI workload capacity. The community is discussing AMD's strengthened position as a leading contender in high-performance AI, reinforced by analyst upgrades, including Wells Fargo naming it a top pick for 2026. This reflects broader market optimism around insatiable demand for data center computing, where AMD is carving out substantial growth.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending amid renewed uncertainty regarding H200 chip sales to China, with reports of blocked shipments fueling investor concern. This adds to broader market volatility stemming from escalating geopolitical tariff threats, prompting community discussion on the immediate impact versus the company's long-term AI leadership. While some see a buying opportunity fueled by NVIDIA's strong product pipeline, others remain cautious about potential market disruptions.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Holdings Inc

Ondas Holdings is trending following its Investor Day, where the company announced significantly raised revenue guidance for 2026 and a substantial increase in its backlog, alongside a billion-dollar offering that reflects strong institutional confidence in its strategic defense technology acquisitions. The community is sharply divided, with bulls emphasizing the firm's combat-proven drone and counter-UAS capabilities for future growth, while others express concern over stock volatility and valuation, leading to a mixed market reaction to its updated outlook.

Venus Concept, Inc. is a global medical technology company, which engages in the business of developing, commercializing, and selling minimally invasive and non-invasive medical aesthetic and hair restoration technologies. It operates under the United States and International geographical segments. The company was founded on November 22, 2002 and is headquartered in Toronto, Canada.

Venus Concept Inc

Venus Concept ($VERO) is a major trending topic following news of Madryn Asset Management's reported 91% stake, which has drastically tightened the public float. This has fueled intense bullish speculation about an unprecedented short squeeze and significant price appreciation, with many believing shorts are now powerless. Conversely, a vocal group highlights concerns over the company's fundamentals and the potential for the majority shareholder to pursue delisting or privatization at a lower value, leading to extreme volatility and passionate debate.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending amid heightened cryptocurrency market volatility driven by ongoing geopolitical tariff discussions, prompting debates around its resilience and independence from Bitcoin. Community members are sharply divided, with many actively accumulating during dips, confident in its long-term utility and potential for institutional adoption, while skeptics highlight concerns over its large supply and past price performance, labeling it a "scam." The impending Clarity Act draft and Ripple's presence at the World Economic Forum are key catalysts fueling conversation about its future in global financial infrastructure.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is trending after its recent AGM, where a significant increase in authorized shares passed alongside the announcement of a $200 million investment in MrBeast Industries. This has fueled a polarized community discussion, with concerns over potential dilution and the company's strategic direction clashing against long-term bullish sentiment for its Ethereum treasury holdings. The controversy leaves many questioning the immediate impact on BMNR's perceived connection to Ethereum's performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cartesian Therapeutics, Inc. (RNAC) Upgraded to Buy: What Does It Mean for the Stock?

Cartesian Therapeutics, Inc. (RNAC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) have been given an average recommendation of "Moderate Buy" by the five research firms that are currently covering the firm...

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) have received an average recommendation of "Moderate Buy" from the six brokerages that are presently covering the firm...

What is HC Wainwright's Estimate for RNAC FY2025 Earnings?

Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) - Investment analysts at HC Wainwright cut their FY2025 earnings per share estimates for Cartesian Therapeutics in a research note issued on...

HC Wainwright Issues Pessimistic Forecast for Cartesian Therapeutics (NASDAQ:RNAC) Stock Price

HC Wainwright cut their price target on Cartesian Therapeutics from $40.00 to $30.00 and set a "buy" rating for the company in a report on Wednesday...

Cartesian Therapeutics (NASDAQ:RNAC) Given New $44.00 Price Target at BTIG Research

BTIG Research increased their price objective on Cartesian Therapeutics from $42.00 to $44.00 and gave the company a "buy" rating in a research note on Friday...

Cartesian Pauses Lupus And Multiple Myeloma Studies As It Shifts Development Focus

Cartesian Therapeutics shared initial data from Phase 2 trial of Descartes-08, showing potential for treating systemic lupus erythematosus.read more...

Cantor Fitzgerald Issues Negative Estimate for RNAC Earnings

Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) - Stock analysts at Cantor Fitzgerald decreased their FY2025 earnings estimates for Cartesian Therapeutics in a research report issued to...

Wedbush Has Negative Forecast for RNAC FY2025 Earnings

Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) - Research analysts at Wedbush cut their FY2025 earnings estimates for shares of Cartesian Therapeutics in a note issued to investors on...

Cartesian Therapeutics (NASDAQ:RNAC) Announces Quarterly Earnings Results, Misses Estimates By $0.57 EPS

Cartesian Therapeutics (NASDAQ:RNAC - Get Free Report) announced its earnings results on Thursday. The company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of...

Cartesian Therapeutics, Inc. operates as a clinical-stage biotechnology company. It provides mRNA cell therapies for the treatment of autoimmune diseases. It operates in research and development of cell therapy product candidates. The company is headquartered in Gaithersburg, MD.

Current Price	$7.42
Prev Close	$7.36
Open	$7.53
Dividend Yield	0.00%
50-Day Moving Average	$7.38
Beta	1.75
Avg. Volume	255,984.36
PE Ratio	-0.14

52-Week High	$20.00
52-Week Low	$5.98
Market Capitalization	$192.95M
EPS (Annual)	-$4.48
Price to Book	-5.38
Revenue Per Employee	$589,590.91
Enterprise Value/EBITDA	N/A

RNAC
Selecta Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RNAC News

RNACSelecta Biosciences Inc